Sidelining safety--the FDA's inadequate response to the IOM

N Engl J Med. 2007 Sep 6;357(10):960-3. doi: 10.1056/NEJMp078157.

¹ Center on Drugs and Public Policy, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, USA.

No abstract available

MeSH terms

Drug Approval* / legislation & jurisprudence
Drug Approval* / methods
Drug-Related Side Effects and Adverse Reactions*
Government Regulation
Models, Organizational
National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division*
Organizational Innovation
Product Surveillance, Postmarketing
United States
United States Food and Drug Administration / organization & administration*
United States Food and Drug Administration / standards